Transgene Biotek Ltd
Incorporated in 1990, Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.[1]
- Market Cap ₹ 31.7 Cr.
- Current Price ₹ 4.18
- High / Low ₹ 10.8 / 3.22
- Stock P/E
- Book Value ₹ 1.32
- Dividend Yield 0.00 %
- ROCE -1.75 %
- ROE -6.56 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.16 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
- Company has a low return on equity of -20.5% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.98 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | |
2.81 | 1.90 | 1.32 | 2.84 | 2.22 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.83 | 1.38 | |
Operating Profit | -1.83 | -1.60 | -1.14 | -2.56 | -2.10 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.60 | -1.12 |
OPM % | -186.73% | -533.33% | -633.33% | -914.29% | -1,750.00% | -971.43% | -311.76% | -511.11% | -1,033.33% | -260.87% | -430.77% | |
-114.37 | 0.01 | 0.17 | 0.66 | 7.37 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | |
Interest | 0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 |
Depreciation | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 |
Profit before tax | -133.42 | -19.13 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -0.65 | -0.67 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
-133.41 | -19.14 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -0.66 | -0.68 | |
EPS in Rs | -17.61 | -2.53 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -1% |
5 Years: | % |
3 Years: | 42% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 14% |
3 Years: | 25% |
TTM: | -3% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | 5% |
3 Years: | 4% |
1 Year: | -35% |
Return on Equity | |
---|---|
10 Years: | -19% |
5 Years: | -34% |
3 Years: | -21% |
Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
Reserves | 130.20 | 115.62 | 98.67 | -16.90 | -23.34 | -32.13 | -43.10 | -53.53 | -58.39 | -64.40 | -65.06 | -65.74 |
13.06 | 14.43 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | 14.00 | 14.52 | |
139.32 | 137.95 | 123.27 | 123.18 | 124.28 | 123.77 | 123.75 | 123.31 | 117.71 | 117.87 | 117.62 | 119.54 | |
Total Liabilities | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 |
180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 9.83 | |
CWIP | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.10 | 0.10 | 0.10 |
177.48 | 180.08 | 171.75 | 134.86 | 133.71 | 133.58 | 133.68 | 133.69 | 133.73 | 133.93 | 134.00 | 134.16 | |
Total Assets | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-2.11 | 3.52 | 6.47 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | 0.00 | 1.20 | |
1.45 | -4.57 | -6.47 | 0.00 | 3.05 | 1.74 | 0.00 | -0.03 | -0.10 | -0.01 | 0.00 | -1.70 | |
0.60 | 1.03 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | |
Net Cash Flow | -0.05 | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.01 | 0.00 | -0.01 | 0.00 | 0.28 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 6,797.19 | 19,953.33 | 3,325.56 | 13.04 | 30.42 | 52.14 | 21.47 | 40.56 | 60.83 | 15.87 | 14.04 | |
Inventory Days | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | ||||||
Days Payable | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | ||||||
Cash Conversion Cycle | -19,072.18 | 19,953.33 | 3,325.56 | 13.04 | -4,623.33 | -3,111.19 | -1,316.86 | 40.56 | -982.02 | 15.87 | 14.04 | |
Working Capital Days | 648.06 | 1,399.17 | 2,108.89 | -1,864.11 | -21,717.50 | -36,239.29 | -14,514.12 | -5,231.67 | -7,725.83 | -1,777.39 | -4,688.85 | |
ROCE % | -6.48% | -8.83% | -10.86% | -14.69% | -10.97% | -17.91% | -22.11% | -26.56% | -32.31% | -20.01% | -2.07% | -1.75% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 May - Newspaper Advertisement of Financial Results under Regulation 47 of SEBI (LODR), 2015.
- Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2025 7 May
-
Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2025
7 May - Audited FY25 results: Rs. 67.61L loss; Rs. 203 Cr penalty under appeal; clinical studies progressing well.
-
Board Meeting Intimation for Intimation Of The Board Meeting Of The Company.
This Is To Inform You That A Meeting Of Board Of The Company Will Be Held On Wednesday 07Th May 2025.
26 Apr - Board meeting on May 7, 2025 to approve audited Q4 and FY 2025 financial results.
-
Compliance-57 (5) : intimation after the end of quarter
26 Apr - Company states SEBI Reg 57(5) not applicable; no non-convertible securities issued as of March 31, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Expertise:[1]
Company is in production and oral formulation of different proteins using TrabiORAL technology
a) Oncology[2]
b) Auto Immunity[3]
c) Drug Delivery[4]
d) Biogenerics[5]